Developmental therapeutics Poster lunch Poster Display session

141P - Erbitux conjugated zinc oxide nanoparticles to enhance antitumor efficiency via targeted drug delivery system for breast cancer therapy (ID 1700)

Presentation Number
141P
Presentation Topic
Developmental therapeutics
Lecture Time
13:00 - 13:00
Speakers
  • K. Vimala
Authors
  • K. Vimala
  • K. Soundarapandian
Session Title
Session Room
Exhibition area, Singapore, Singapore, Singapore
Date
18.11.2017
Session Time
13:00 - 14:00

Abstract

Background

Owing to the presence of multidrug resistance in tumor cells, conventional chemotherapy remains clinically intractable. To enhance the therapeutic efficacy of chemotherapeutic agents, targeting strategies based on polyethylene glycol coated zinc oxide nanoparticles modified with targeting ligands have gained significant attention in cancer therapy

Methods

We used the green‐bio method to synthesize folic acid modified erbitux conjugated zinc oxide nanoparticles complex for its use as a cancer‐targeted drug delivery system to achieve enhanced cellular uptake and anticancer efficacy. To investigate the expression level of E2F3 protein RT‐PCR and western blotting analysis was carried out.

Results

In the present investigation, we synthesized folic acid (FA)-modified polyethylene glycol coated zinc oxide nanoparticles (PEG-ZnO NPs) loaded with erbitux (ErB) using a bio organic method, followed by FA adsorption on the surface of NPs. The FA-modified PEG-ZnO NPs were characterized in terms of particle morphology and size, encapsulation efficiency and drug release. Furthermore, the cytotoxicity and cellular uptake of the drug-loaded PEG-ZnO NPs were evaluated in breast cancer cells in vitro. We found that FA-modified ErB-PEG-ZnO NPs showed the highest cytotoxicity effect and cellular uptake efficiency under folic acid receptor mediation in breast cancer cells compared with unmodified PEG-ZnO NPs and free drug. The cellular uptake efficiency of FA-modified PEG-ZnO NPs appeared to be facilitated by the applied PEG-ZnO NPs field, but the difference did not reach statistical significance.

Conclusions

This study illustrates that this proposed formulation can be used as one new alternative treatment for patients bearing inaccessible tumors. Thus, functionalized-ZnO NPs could be used as a novel nanomaterial for selective chemotherapy.

Clinical trial indentification

622/PO/c/02/CPCSEA/2014.

Clinical trial identification

622/PO/c/02/CPCSEA/2014.

Legal entity responsible for the study

Periyar University, Department of Zoology, Division of Cancer Nanomedicine

Funding

None

Disclosure

All authors have declared no conflicts of interest.

Collapse